BAYRY Stock UPDATES Bayer Aktienges Ads (BAYRY) 128.9100 08/10/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bayer Aktienges Ads (BAYRY) 128.9100 $BAYRY

Regeneron Misses on Earnings in Q2, Eylea Drives Sales Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 2:02PM CDT
Regeneron (REGN) recorded higher than expected revenues due to strong Eylea sales.

Bayer Corporation Donates $100,000 to the American Red Cross to Support Disaster and Emergency Preparedness
PR Newswire - Tue Aug 05, 7:00AM CDT
Bayer Corporation today announced a $100,000 donation to the American Red Cross to support the organization's national disaster and emergency preparedness efforts across the United States.

Bayer Earnings Grow Marginally Y/Y, New Products Encourage - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:41AM CDT
Bayer's (BAYRY) newly launched products performed well in the quarter.

Global Acaricides Market - Forecasts to 2019
M2 - Thu Jul 31, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bdkmx2/acaricides_market) has announced the addition of the "Acaricides Market by Type, by Application, by Mode of Action & Geography - Trends & Forecasts to 2019" report to their offering. Chemicals that are used to kill ticks and mites are known as acaricides. They help in increasing productivity by keeping animals and crops healthy and disease-free. Cattle, when treated with acaricides are less susceptible to tick-borne diseases and there is an increase in the milk and other product yield. The acaricides market is growing steadily due to increase in the demand of the crops and animal products. Factors that act as driving forces for this market are the increase in productivity, development in the crop protection industry, and the growing demand of crops and animal products across the world. The high cost of raw materials and the strict regulatory norms imposed by some governments pose as hindrances for this market. Various secondary sources such as encyclopedias, directories, and databases, were used to identify and collect information useful for this extensive market-oriented study of the acaricides market. The primary sources-experts from related industries and suppliers-were interviewed to obtain and verify critical information as well as to assess the future prospects of the global acaricides market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Analysis 5 Market Overview 6 Industry Analysis 7 Acaricides Market, By Type 8 Acaricides Market, By Application 9 Acaricides Market, By Mode of Action 10 Acaricides Market, By Geography 11 Competitive Landscape 12 Company Profile Companies Mentioned: - Arysta Lifescience - BASF SE - Bayer AG - Chemtura Corporation - Dupont - FMC Corporation - Merck & Co., Inc. - Nissan Chemical Industries, Ltd. - Syngenta AG - The Dow Chemical Company For more information visit http://www.researchandmarkets.com/research/bd...des_market

Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 6:00PM CDT
Regeneron Pharmaceuticals, Inc.'s (REGN) eye drug Eylea received FDA approval for a third indication: the treatment of diabetic macular edema.

Amgen Restructuring Plan, Q2 Earnings Send Stock Up
at Investor's Business Daily - Wed Jul 30, 10:20AM CDT
Amgen (AMGN) was up more than 5%, near 129, in early trading in the stock market today as analysts approved of big-cap biotech's earnings beat and restructuring plans announced late Tuesday. Earlier, Amgen stock touched a new high above 131. Amgen's...

Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals
M2 - Wed Jul 30, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqg93q/global_retinal) has announced the addition of the "Global Retinal Vein Occlusion Market 2014-2018" report to their offering. Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Portfolio 08. Rate of Incidence and Prevalence 09. Market Segmentation by Type of Therapy 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Forms 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. - Alimera Sciences - Bristol-Myers Squibb - NicOx - Santen Pharmaceutical Co. - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/rq...al_retinal

European Stocks Steady as Barclays Reports, AstraZeneca Buys Generic Line
at The Street - Wed Jul 30, 5:31AM CDT
European stock indices were little changed on Wednesday as a new round of U.S. and European Union sanctions against Russia over Ukraine coincided with a slew of corporate earnings.

Merck, Pfizer Ramping R&D After Q2 Earnings Beat
at Investor's Business Daily - Tue Jul 29, 4:32PM CDT
Big pharmas Merck and Pfizer modestly beat Q2 estimates early Tuesday, and both guided the full year cautiously as they prepare for new drug launches. Merck stock rose 1.1%, but Pfizer stock fell 1.2%. Merck's (MRK) earnings totaled 85 cents a share,...

Merck (MRK) Tops Q2 Earnings Expectations on Cost Cuts - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Jul 29, 11:30AM CDT
Merck's (MRK) second quarter results were better-than-expected even though the company is facing generic competition for quite a few products.

Global Synthetic Biology Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4xp9d8/global_synthetic) has announced the addition of the "Global Synthetic Biology Market 2014-2018" report to their offering. The term synthetic biology covers the designing and engineering of completely new biological parts, devices, and organisms as well as the redesigning of natural biological systems that provide improved and desirable functions. It is considered to be a form of extreme genetic engineering because it not only alters existing metabolic pathways, but also creates new ones. The engineered biological systems can be used to manipulate chemicals, fabricate materials and structures, produce energy, provide GM food, improve the efficiency of drugs and vaccines, and maintain a sustainable environment. The analysts forecast the Global Synthetic Biology market will grow at a CAGR of 33.8 percent over the period 2013-2018. The Global Synthetic Biology market can be categorized on the basis of technology into four segments: Genome Engineering. DNA Sequencing, Bioinformatics, and Biological Components and Integrated Systems. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Technology 08. Market Segmentation by Product 09. Market Segmentation by Applications 10. Geographical Segmentation 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - Amyris Inc. - E. I. du Pont de Nemours and Co. - Thermo Fisher Scientific Inc. - Synthetic Genomics Inc. - Algenol Biofuels Inc. - ATG:biosynthetics GmbH - Bayer AG - Bioneer Corp. - Biosearch Technologies Inc. - Bristol-Myers Squibb Co. - CBC Comprehensive Biomarker Center GmbH - Cobalt Technologies - Evolva Holdings SA - Exxon Mobil Corp. - GeneWorks Pty Ltd. - Genomatica Inc. - Gevo Inc. - Ginkgo Bioworks - Green Biologics Ltd. - New England Biolabs Inc. - OriGene Technologies Inc. - REG Life Sciences LLC - Royal DSM - Synthorx Inc. For more information visit http://www.researchandmarkets.com/research/4x..._synthetic

Bayer/Amgen's Nexavar Does Not Show Resilience in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 1:45PM CDT
Bayer (BAYRY) and Amgen's (AMGN) Nexavar performed disppointingly in a late stage study.

Bayer Battles New Insecticide Research Affecting 20% of Sales
at The Street - Wed Jul 23, 9:18AM CDT
Bayer CropSciences' corn seed treatments and flea and tick medicine for pets may be killing birds and bees. The company stands to lose big if the chemical is banned.

Global Women's Health Market 2014-2018
M2 - Wed Jul 23, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kxqgp/global_womens) has announced the addition of the "Global Women's Health Market 2014-2018" report to their offering. The Global Women's Health market will grow at a CAGR of 3.52 percent over the period 2013-2018. Women experience physiological and emotional issues during different phases of their life cycle due to hormonal changes. Women's health is especially referred to where reproductive health is involved. According to the Society for Women's Health Research in the US, issues specific to the human female anatomy are defined as women's health. The biological mechanisms influence the clinical course of diseases and disorders differently in women when compared to men. Some of the main women's health disorders include infertility, menopause, endometriosis and polycystic ovarian syndrome as well as urological disorders and cancers such as breast cancer, cervical cancer, endometrial cancer, and ovarian cancer. In addition, contraception plays an important role in women's health for many reasons, so this too is also categorized under women's health. To calculate the market size, the report considers revenue generated from the sales of various products used for the wellbeing of women, which are listed below based on their application segment: - Postmenopausal Osteoporosis (Drugs) - Hormonal Contraceptives (Drugs and Devices) - Menopause (Drugs) - Infertility (Drugs) - Endometriosis (Drugs) - Polycystic Ovary Syndrome (Drugs) The report, the Global Women's Health Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA, and the APAC regions; it also covers the Global Women's Health market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actavis plc - Bayer AG - Eli Lilly and Co. - Merck & Co. - Pfizer Inc. According to the report, the growth of the Global Women's Health market is curtailed by some serious challenges. One of the main challenges is the patent expiry of major blockbuster drugs during the forecast period. Some of the patent expiries of top leading products include Bayer's Mirena and Yaz, Eli Lilly's Evista, and F. Hoffmann-La Roche's Boniva. For more information visit http://www.researchandmarkets.com/research/4k...bal_womens

Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25

Global Animal Antimicrobials and Antibiotics (Tetracyclines, Penicillins, Sulfonamides, Aminoglycosides) Market 2014-2018
M2 - Wed Jul 23, 4:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4hmcm5/animal) has announced the addition of the "Animal Antimicrobials and Antibiotics Market by Products, Animals & Mode Of Delivery - Global Forecasts to 2018" report to their offering. At present, the global antimicrobials and antibiotics market is driven by the growing need to preserve animal health owing to rising demand for animal proteins across the globe, and growing demand in the companion animals segment. Growing livestock population, increasing incidences of disease outbreaks and increase in the companion animal ownership are some of the factors driving the growth of this market to a certain extent. Besides the structural market drivers, there are strong geographic drivers for the growth of the animal antimicrobials and antibiotics market. Emerging markets are becoming increasingly attractive. The Asian and Latin American region form one of the most promising animal antimicrobials and antibiotics markets in the world. Developing countries such as China and India have a relatively high CAGR rate and are expected to witness significant market growth in the forecast period. The growth in these regions is mainly attributed to the rise in demand for animal protein products, along with an increase in the trend of companion animal ownership in these regions. Today, the animal antimicrobials and antibiotics market showcase a sluggish growth, owing to the regulatory authorities restricting their use, increased usage of in-feed enzymes, competitive exclusion products and probiotics as an alternative to antibiotics and prophylactic use of antibiotics being replaced by good husbandry, environment and hygienic practices. Report Scope Products - Tetracyclines - Penicillins - Sulfonamides - Aminoglycosides Animals - Dog - Poultry - Swine Mode Of Delivery - Premixes - Oral Powders - Solutions - Injections Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Veterinary Antimicrobials And Antibiotics Market, By Product 6 Veterinary Antimicrobials And Antibiotics Market, By Mode Of Delivery 7 Veterinary Antimicrobials And Antibiotics Market, By Type Of Animal 8 Geographic Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned - Bayer Ag - Boehringer Ingelheim - Ceva Sante Animale - Eli Lilly And Company - Merck And Co., Inc. - Novartis Ag - Sanofi - Vetoquinol - Virbac Sa - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/4hmcm5/animal

Bayer/Regeneron Continue to Progress with Eylea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 4:20PM CDT
Bayer (BAYRY) and Regeneron Pharmaceuticals (REGN) announced encouraging results from the phase III study on Eylea.

2014 Global Non-Hodgkin Lymphoma Therapeutics Market Report Featuring Bristol Myers Squibb, Celgen, Eli Lilly and Co, F. Hoffman La-Roche & GSK
M2 - Tue Jul 22, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/52q7th/global) has announced the addition of the "Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018" report to their offering. Non-Hodgkin lymphoma (NHL) is a condition of the human body leading to the production of abnormal lymphocytes. In normal circumstances, the lymphocytes grow and die. However, in NHL they do not die; instead they grow and further divide. NHL can begin either in the T-cells or B-cells, though mostly it begins in the B-cells. The location of NHL is generally in the lymph nodes, but it can also spread to the body's lymphatic system. It has many symptoms, of which swelling in the lymph nodes, abdominal pain, chest pain, cough, fever, fatigue, and night sweats are the most prominent. The causes of this disease are still unknown to scientists. NHL is linked with risk factors such as the overuse of immunosuppressant drugs, viruses such as HIV or Epstein-Barr, and bacteria such as Helicobacter pylori. NHL can be diagnosed by urine tests, physical examination for the enlargement of the lymph nodes, imaging tests (scans) such as magnetic resonance imaging (MRI) or computerized tomography (CT), and biopsy tests. This report covers the present scenario and the growth prospects of the Global Non-Hodgkin Lymphoma Therapeutics market for the period 2014-2018. The Global Non-Hodgkin Lymphoma Therapeutics market will observe a high growth in the forecast period. It is due to the availability of the biosimilars at a reduced price across the NHL market. This will be mainly due to the growth of the drug Rituxan in the global market. Apart from that, the market will also grow as a result of the improved diagnostic techniques to detect NHL. Besides, the increase in public awareness about NHL and robust drug pipeline for the treatment of NHL are the major influencers in the growth of the Global Non-Hodgkin Lymphoma Therapeutics market. The report, the Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-Hodgkin Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Bristol Myers Squibb Co. - Celgene Corp. - Eli Lilly and Co. - F. Hoffman La-Roche Ltd. - GlaxoSmithKline plc Other Prominent Vendors - Accredo Health Group Inc. - Baxter International Inc. - Bayer AG - Cephalon Inc. - Eisai Pharmaceuticals Inc. - Genelabs Technologies Inc. - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Millenium Pharmaceuticals Inc. - Pacira Pharmaceuticals Inc. - Pfizer Inc. - Sanofi SA - Teva Pharmaceuticals Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type of Therapy - Pipeline Portfolio - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/52q7th/global

Global Gynecological Devices Market to 2018: Gynecologic Surgical Devices, Diagnostic Imaging Systems, Gynecological Chairs, and Hand Instrument
M2 - Mon Jul 21, 8:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n4f66s/global) has announced the addition of the "Global Gynecological Devices Market 2014-2018" report to their offering. The Global Gynecological Devices market will grow at a CAGR of 6.63 percent over the period 2014-2018. Gynecological devices have been broadly classified into wide categories based on their operations. These devices are used for the treatment of different gynecological conditions that affect the female reproduction organs, female fertility, menorrhagia (heavy menstrual periods), infections, and disorders such as endometriosis, gestational diabetes, polycystic ovary syndrome, uterine fibroids, and pelvic floor disorders. Every woman faces a gynecological condition at some point in her life. Several conditions may be easily treatable and several may be life threatening. The gynecological devices help by having an impact on a woman's infertility , treat serious illnesses, and treat the devastating consequences that are life threatening. The gynecological devices are made to perform with advanced technologies and procedures to improve the treatment of complex gynecology surgeries. Several devices are portable, disposable, and very easy to handle and can be used in any gynecology centers. This report covers the present scenario and the growth prospects of the Global Gynecological Devices market for the period 2014-2018. The Global Gynecological Devices market can be segmented into four divisions: Gynecologic Surgical Devices, Diagnostic Imaging Systems, Gynecological Chairs, and Hand Instruments. These are sets of methodologies and technologies that transform unstructured and structured data into meaningful and useful information processes. The report, the Global Gynecological Devices Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Gynecological Devices market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Bayer AG - Boston Scientific Corp. - CooperSurgical Inc. - Ethicon Inc. - Hologic Inc. - Medtronic Inc. - Olympus Corp. - Stryker Corp. Other Prominent Vendors - ATMOS MedizinTechnik GmbH & Co. KG - BTL Medical technologies Inc. - KARL STORZ GmbH & Co. KG - Meditelle Medical Equipment Ltd. - Richard Wolf GmbH - Welch Allyn, Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/n4f66s/global

New Study Touts Benefits of Organic Goods, Questions Pesticides and GMOs
Brian Stoffel, The Motley Fool - Motley Fool - Sat Jul 19, 9:24AM CDT
Scientists estimate that we humans—since our earliest ancestors—have been running around the earth for well over two million years. Only within the past century—or 0.005% of that time—have we come to rely so heavily on the use of pesticides to help...




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Max y Noelia Explore Trade at 9th CIIE in Shanghai

Updated Category News Views 110

Influencers at the Heart of Global Trade Exploration Makin' their debut on the big stage of the 9th China International Import Expo (CIIE), Mexican influencers Max y Noelia found themselves caught in a whirlwind of trade and cultural exchanges over in Shanghai. These digital mavens aren't just snapping selfies. Nope, they're capturing the very essence of international...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 115

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 81

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 65

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 231

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 97

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 107

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 149

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 184

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading

Top 5 Most Recently Viewed Articles

Leadership Changes at TTM Technologies Signal New Directions

Updated Category News Views 216

Leadership Transition at TTM Technologies TTM Technologies, Inc. (NASDAQ: TTMI), a prominent player in the technology manufacturing sector, has announced a significant leadership shift within the organization. James P. Walsh, known as Jim, will take on the role of Chief Operating Officer on a scheduled date, while the outgoing COO, Philip Titterton, will remain engaged in...

Continue Reading
Bernie Sanders and Geoffrey Hinton Discuss AI's Future Impact

Updated Category News Views 348

Examining the Role of AI in Society In a recent engaging forum, Sen. Bernie Sanders and AI expert Geoffrey Hinton opened a dialogue about the future of artificial intelligence and its impact on the workforce. They focused on a critical question: Who truly benefits from the advancements in AI technology? Concerns Regarding Control of AI During their discussion, Sanders...

Continue Reading
Join the Melts™ Affiliate Program and Talent Search Today

Updated Category News Views 194

Melts™ Launches an Innovative Affiliate Program Melts™, a contemporary wellness brand, is changing the landscape of supplement delivery with its unique oral dissolvable strips. Today, Melts announced the exciting launch of its open affiliate program, complemented by a nationwide talent search aimed at enhancing its visibility and brand influence. This initiative...

Continue Reading
Navigating Economic Uncertainty Amid Mixed Signals and Shutdown

Updated Category News Views 126

Understanding Current Economic Trends As the government shutdown continues, we face a uniquely challenging landscape in the economy. Policymakers and investors are wrestling with conflicting signals, as a weak labor market exists alongside rising inflation. Over the past year, the S&P 500 has shown remarkable resilience with a nearly 40 percent increase, marking...

Continue Reading
Sharp Decline in Gold and Silver Prices: What You Should Know

Updated Category News Views 174

The Recent Crisis in Gold and Silver Values Gold and silver have taken center stage in investor conversations recently, witnessing a significant decline that rattled markets. Both precious metals experienced a dramatic downturn, influenced by various market dynamics that forced many investors holding leveraged positions to liquidate their assets. The drop in gold prices...

Continue Reading